MCE products for research use only. We do not sell to patients.

Stemregenin 1

MCE China：Stemregenin 1

Brand：MedChemExpress (MCE)

Cat. No.HY-15001

CAS：1227633-49-9

Synonyms：SR1

Purity：99.95%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with IC50 of 127 nM.

In Vitro：Stemregenin 1 (SR1) acts by antagonizing the aryl hydrocarbon receptor (AhR). Stemregenin 1 increases the number of CD34+ cells after 5 to 7 days with an EC50 of ~120 nM. Stemregenin 1 inhibits photoaffinity ligand (PAL) binding (IC50=40 nM) These results support the conclusion that Stemregenin 1 -induced CD34+ cell expansion is mediated through direct binding and inhibition of the AhR[1]. An aryl hydrocarbon receptor antagonist, Stemregenin 1 (SR1), robustly promotes ex vivo expansion of human CD34+ cells. Stemregenin 1 treatment accelerates the proliferation of CD34+ cells and decreases the expression levels of VentX[2].

Cell Assay：A quantity of 250,000 CB-derived CD34+ cells are cultured with control conditions (DMSO, 0.01%) or StemRegenin 1 (0.75 μM) for 3 weeks. At this point control cultures had expanded 1080-fold and StemRegenin 1 treated cells expanded 2024-fold relative to starting cell numbers. A quantity of 30 to 30,000 uncultured CD34+ CB-derived cells or a fraction of the final culture equivalent to 30 to 10,000 starting cells are transplanted. The cells are injected intravenously via the retro-orbital route into sub-lethally irradiated (300 rads, 200 rads) 6- to 10-week-old NSG mice. Engraftment is performed within 24 h after irradiation. Engraftment is monitored by flow cytometric analysis of blood obtained via retro-orbital sinus or bone marrow using anti-human CD45 and anti-mouse CD45 antibodies. The mice are sacrificed between 13-16 weeks posttransplantation; bone marrow (from both femurs and tibiae), spleen and thymus are collected for analysis. For secondary engraftment, 50% of the bone marrow from each recipient mouse is transplanted into one secondary sub-lethally irradiated NSG mouse. Fifteen weeks after transplantation, bone marrow is harvested from the secondary mice and analyzed by flow cytometry[1].

IC50 & Target：IC50: 127 nM (AhR)[1] In Vitro Stemregenin 1 (SR1) acts by antagonizing the aryl hydrocarbon receptor (AhR). Stemregenin 1 increases the number of CD34+ cells after 5 to 7 days with an EC50 of ~120 nM. Stemregenin 1 inhibits photoaffinity ligand (PAL) binding (IC50=40 nM) These results support the conclusion that Stemregenin 1 -induced CD34+ cell expansion is mediated through direct binding and inhibition of the AhR[1]. An aryl hydrocarbon receptor antagonist, Stemregenin 1 (SR1), robustly promotes ex vivo expansion of human CD34+ cells. Stemregenin 1 treatment accelerates the proliferation of CD34+ cells and decreases the expression levels of VentX[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Stemregenin 1 Related Antibodies

Hot selling product：Rasagiline  | Afatinib (dimaleate)  | Nicotiflorin  | TAK-285  | Perindopril (erbumine)  | L-Lysine hydrochloride  | Baloxavir marboxil  | Sophocarpine  | KOdiA-PC  | (-)-p-Bromotetramisole (oxalate)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Boitano AE, et al. Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells. Science. 2010 Sep 10;329(5997):1345-8.  [Content Brief]

[2]. Gao H, et al. Suppression of homeobox transcription factor VentX promotes expansion of human hematopoietic stem/multipotent progenitor cells. J Biol Chem. 2012 Aug 24;287(35):29979-87.  [Content Brief]